We want to make effective treatment optimization accessible to every European citizen

Our focus

We want to improve the safety and efficacy of pharmacotherapy for every European patient by enabling clinical pharmacogenomics
Shared European Guidelines

Maintenance and dissemination of pharmacogenomics guidelines in the European Union

Implementation and Evaluation

Clinical implementation and outcome evaluation of pre-emptive pharmacogenomics in a multitude of European countries

Enabling technologies

Development of powerful and barrier-free clinical decision support systems and novel pharmacogenomics methodologies

Communication and education

Development of a program to reach out to patients, health care professionals, regulatory agencies, politics and health insurance organisations

The project

Pharmacogenomics (PGx) is the study of genetic variability affecting an individual’s response to a drug. Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in PGx and several commercially available PGx tests, its application in routine patient care remains very limited.
Immediate knowledge of relevant PGx variation, with interpretation and recommendations, without any disruption of routine clinical care is a clear advantage of the U-PGx approach.

The U-PGx consortium will address major challenges and obstacles for implementation of PGx testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. With the pre-emptive PGx testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive PGx-testing will be conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia).

  • Potential optimization

    50% of elderly patients will receive drug treatment that could be optimized via PGx within the next four years.

  • Physician interest

    98% of physicians think that PGx could help to better predict drug response.

  • Lack of knowledge

    Only 10% of physicians feel they currently have adequate knowledge and tools for PGx.

Our Team

A strong and efficient team of expert researchers, clinicians, companies and stakeholders
Henk-Jan Guchelaar
Scientific coordinator, U. Medical Centre Leiden, NL
Jesse Swen
U. Medical Centre Leiden, NL
Sir Munir Pirmohamed
U. of Liverpool, UK
Julia Stingl
Federal Institute for Drugs and Medical Devices, GER
Magnus Ingelman-Sundberg
Karolinska Institute, SWE
Christina Mitropoulou
Golden Helix Foundation, UK
Ka-Chun Cheung
KNMP Holding B.V., NL
Matthias Samwald
Medical University of Vienna, AUT
Anne Cambon-Thomsen
U. of Toulouse, FR
Mats Karlsson
Uppsala University, SWE
Giuseppe Toffoli
National Cancer Institute, ITA
Cristina Lucía Dávila-Fajardo
S. C. University Hospital Granada, ESP
George P. Patrinos
University of Patras, GRE
Vita Dolžan
University of Ljubljana, SLO
Matthias Schwab
U. of Stuttgart, GER
Marjolein Kriek
U. Medical Centre Leiden, NL
Wendy van Hemmen
Project manager, U. Medical Centre Leiden, NL
Cathelijne van der Wouden
U. Medical Centre Leiden, NL
Richard Turner
U. of Liverpool, UK
Mandy van Rhenen
KNMP Holding B.V., NL
Gere Sunder-Plassmann
Medical University of Vienna, AUT
Kathrin Blagec
Medical University of Vienna, AUT
Sebastian Hofer
Medical University of Vienna, AUT
Siv Jonsson
Uppsala University, SWE
Erika Cecchin
National Cancer Institute, ITA
Carlos Gonzalez
Theodora Katsila
University of Patras, GRE
Barbara Jenko
Frans van der Vaart
Royal Dutch Pharmacists Association, NL
Daniela Steinberger
Bio.logis Center for Human Genetics, GER
Vera Deneer
St. Antonius Hospital Nieuwegein, NL

Advisory board